PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Remarkably, many of these patients are highly responsive to checkpoint blockade treatment (Diaz and Le, 2015; Le et al., 2017; Le et al., 2015) where the tumor infiltrating CD8+ cytotoxic T cells can be reactivated by anti-PD1 antagonists to effectively eradicate tumors.”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Diaz and Le, 2015
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cited by
Items 201–300 of 435
Andoni, T., Wiggins, J. M., Robinson, R., Charlton, R. S., Sandberg, M., & Eeles, R. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06376-4 · Cited by 23
Ragusa, F., Ferrari, S. M., Elia, G., Paparo, S. R., Balestri, E., Botrini, C., Patrizio, A., Mazzi, V., Guglielmi, G., Foddis, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105731 · Cited by 21
Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
Liu, F., Zhong, F., Wu, H., Che, K., Shi, J., Wu, N., Fu, Y. S., Wang, Y., Hu, J. Y., Qian, X., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac268 · Cited by 22
“Age, years, median (range) 51 (35-81) 48 (23-75) 68 (43-86)”
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
Immune cell infiltration-associated signature in colon cancer and its prognostic implications
Deng, D., Luo, X., Zhang, S., & Xu, Z. (2021) · Aging · doi:10.18632/aging.203380 · Cited by 22
Liu, J., Zhong, L., Deng, D., Zhang, Y., Yuan, Q., & Shang, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-33213-z · Cited by 21
Immune based therapy for melanoma
Ancuceanu, R., & Neagu, M. T. (2016) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.180197 · Cited by 21
Brain metastases in newly diagnosed colorectal cancer: a population-based study
Yang, L., He, W., Xie, Q., Liu, S., Kong, P., Jiang, C., Zhang, B., & Xia, L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s180173 · Cited by 20
The prognostic significance of tumor-infiltrating lymphocytes in cervical cancer
He, M., Wang, Y., Zhang, G., Cao, K., Yang, M., & Liu, H. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e32 · Cited by 22
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018
Yuan, Y., Wang, X., Chen, G., Wang, Y., Sheng, W., Li, X., Zhou, A., Zhang, Z., Li, G., Cai, S., et al. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.03.03 · Cited by 23
Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi, L., Yang, L., Wu, Z., Xu, W., Song, J. H., & Guan, W. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.023 · Cited by 22
“tumors has been proved to be associated with high responding rates to immunotherapy in some clinical trials [104].”
BackgroundIntegration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 21
Luo, M. (2024) · American Journal of Cancer Research · doi:10.62347/myza2640 · Cited by 21
“For CRC, the Keytruda (pembrolizumab, anti-PD-1 monoclonal anti - body) has demonstrated remarkable responses in patients with dMMR/MSI-H [49, 50].”
BackgroundLiu, R., Peng, K., Yu, Y., Liang, L., Xu, X., Li, W., Yu, S., & Liu, T. (2018) · BioMed Research International · doi:10.1155/2018/5920608 · Cited by 20
Chen, G., Wang, L., Diao, T., Chen, Y., Cao, C., & Zhang, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.11605 · Cited by 20
Dong, X., Song, J., Chen, B., Qi, Y., Jiang, W., Li, H., Zheng, D., Wang, Y., Zhang, X., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592811 · Cited by 19
“The absence of tumor antigens (10), antigen presentation defects (11), mismatch repair deficiency (12), overall mutational load, neoantigen load (13, 14), PD-L1 levels (15), intestinal microbiota (16), etc.”
Jiang, H., Pang, J., Li, T., Akofala, A., Zhou, X., Yi, C., Ning, S., Gao, X., Qiao, Y., & Kou, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06469-4 · Cited by 20
MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer
Lü, N., Liu, J., Ji, C., Wang, Y., Wu, Z., Yuan, S., Xing, Y., & Diao, F. (2021) · Bioengineered · doi:10.1080/21655979.2021.1947940 · Cited by 19
Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
Li, J., & Xu, X. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s408349 · Cited by 18
Lü, Z., Chen, H., Jiao, X., Wang, Y., Wu, L., Sun, H., Li, S., Gong, J., Li, J., Zou, J., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00997-6 · Cited by 22
Dang, Y., Yu, J., Zhao, S., Cao, X., & Wang, Q. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02519-9 · Cited by 18
Wang, J., Millstein, J., Yan, Y., Stintzing, S., Arai, H., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Mancao, C., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101827 · Cited by 17
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5802-2 · Cited by 20
The Mechanisms for the Association of Cancer and Esophageal Dysmotility Disorders
Tustumi, F., de Sousa, J. H. B., Dornelas, N. M., Rosa, G. M., Steinman, M., & Bianchi, E. T. (2021) · Medical Sciences · doi:10.3390/medsci9020032 · Cited by 17
“This finding may point to future immunotherapy options for these patients since microsatellite instability is a surrogate prognostic biomarker for immunotherapy in other cancer types [35].”
Griffith, B. D., Turcotte, S., Lazarus, J., Lima, F., Bell, S., Delrosario, L., McGue, J. J., Krishnan, S., Oneka, M. D., Nathan, H., et al. (2022) · Cancers · doi:10.3390/cancers14174092 · Cited by 19
“Immune-based therapies have been effective only for a small subset of patients with mCRC [25], highlighting the need to better understand the immune microenvironment.”
BackgroundWang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 17
Current State of Immune-Based Therapies for Glioblastoma
Lim, M. K., Weller, M., & Chiocca, E. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_159084 · Cited by 17
Chen, B., Zhao, H., Huang, J., Lv, H., Xu, W., Nie, C., Wang, J., Zhao, J., He, Y., Wang, S., et al. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03637-9 · Cited by 16
Satapathy, S. R., Ghatak, S., & Sjölander, A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01157-6 · Cited by 17
Dai, N.-N., Hu, M.-Y., Wang, J., Dai, Z.-H., Xu, L., & Ye, T. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04108-x · Cited by 17
Anker, J. F., Pal, S. K., Kim‐Schulze, S., Wang, H., Halperin, R. F., Uzilov, A. V., Imai, N., Eikawa, S., Saito, T., Sebra, R., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007613 · Cited by 15
Immune checkpoint inhibitor induced colitis: A nationwide population-based study
Farha, N., Alkhayyat, M. M., Lindsey, A. S., Mansoor, E., & Saleh, M. A. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101778 · Cited by 15
Qiao, P., Kaisai, T., Han, L., Ma, B., Shen, C., Zhao, R., Zhang, Y., Wei, W., & Chen, X.-P. (2022) · Endocrine · doi:10.1007/s12020-022-03031-w · Cited by 15
Gao, A., Wang, X., Wang, J., Zhong, D., & Zhang, L. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15408 · Cited by 14
The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia
Cocks, M. M., & Mills, A. M. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000782 · Cited by 14
Sun, Z., Chu, Y., Xiao, J., Yang, Y., Meng, F., Wang, X., Dong, Y., Zhu, J., Wu, Y., Qin, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04504-w · Cited by 15
A novel 4-gene prognostic signature for hypermutated colorectal cancer
Ge, W., Cai, W., Bai, R., Hu, W., Wu, D., Zheng, S. S., & Hu, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s190963 · Cited by 15
Ma, J., Wu, D., Liu, Y., & Zhang, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679365 · Cited by 15
Yang, Z. Q., Xu, D., Ye, X., Lin, X., Zhang, M., Su, Y. A., Xie, Q., & Ni, W. (2022) · BioMed Research International · doi:10.1155/2022/3924400 · Cited by 13
RetractedDeng, Z., Liu, J., Yu, Y. V., & Jin, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1451103 · Cited by 15
Tian, Y., Qi, H., Zhu, N., Yan, X., Guo, L., Wang, L., Teng, X., Xiang, X., Zhu, L., Yuan, Y., et al. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.07.013 · Cited by 13
Ye, S., Wang, H., He, K., Peng, M., Wang, Y., Li, Y., Jiang, S., Li, J., Yi, L., & Cui, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.533282 · Cited by 13
Kumari, R., Xu, X., & Li, H. (2022) · Current Protocols · doi:10.1002/cpz1.431 · Cited by 13
Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors
Babiker, H. M., McBride, A., Cooke, L. S., & Mahadevan, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360275 · Cited by 14
Duan, X.-C., Peng, L., Yao, X. S., Xu, M.-Q., Li, H., Zhang, S., Li, Z.-Y., Wang, J., Feng, Z., Wang, G., et al. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1909180 · Cited by 13
Xu, X., Zhou, N., Lan, H., Yang, F., Dong, B., & Zhang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179767 · Cited by 13
Moschetta, M., Mak, G., Hauser, J., Davies, C., Uccello, M., & Arkenau, H. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0061-2 · Cited by 12
Kim, H., Kim, J., Byeon, S., Jang, K., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., et al. (2021) · Oncology · doi:10.1159/000514404 · Cited by 14
Yang, H., Yu, M. Y., Zhong, S., You, Y., & Feng, F. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-00955-9 · Cited by 12
Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice
Leicher, L. W., Lammertink, M. H. A., Offerman, S. R., Morreau, H. M., de Jong, M. M., de Groot, J. W. B., van Westreenen, H. L., Vasen, H. F. A., & Cappel, W. H. D. V. T. N. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1406534 · Cited by 13
Shi, Y., Ba, Y., Wang, J., Xiong, J., Gu, K., Chen, Y., Zheng, Z., Wang, Z., Guo, W., Cheng, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02229-4 · Cited by 12
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD
Chen, M., Zhang, X., Ming, Z., Lingyu, Feng, X., Han, Z., & An, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05103-z · Cited by 11
Steele, C. W., Whittle, T., & Smith, J. J. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.16 · Cited by 14
Parilla, M., & Ritterhouse, L. L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00370 · Cited by 12
Cai, X., Wei, B., Li, L., Chen, X., Yang, J., Li, X., Jiang, X., Lv, M., Li, M., Lin, Y., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266549 · Cited by 12
Abidi, A., Gorris, M. A. J., Brennan, E., Jongmans, M. C. J., Weijers, D., Kuiper, R. P., de Voer, R. M., Hoogerbrugge, N., Schreibelt, G., & de Vries, I. J. M. (2021) · Cancers · doi:10.3390/cancers13102345 · Cited by 12
Ryan, N. A. J., Walker, T. D. J., Bolton, J., ter Haar, N. T., van Wezel, T., Glaire, M. A., Church, D. N., Evans, D. G., Bosse, T., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13184538 · Cited by 12
Review on the Immunotherapy Strategies Against Metastatic Colorectal Carcinoma
Signorini, L., Delbue, S., Ferrante, P., & Bregni, M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0045 · Cited by 12
Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
Weishan, H., Dong-lin, Z., Guangmei, D., Liu, W., Wu, F., & Chen, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03337-9 · Cited by 10
Zhao, J., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988246 · Cited by 12
Wang, Z., Shao, Y., Zhang, H., Lu, Y., Chen, Y., Shen, H., Huang, C., Wu, J., & Fu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181985 · Cited by 10
“Clinical trials have demonstrated that immunotherapy is effective for MSI-H/dMMR CRC patients (62, 63).”
BackgroundNovel Immunotherapies for the Treatment of Melanoma
Gato, M., Arasanz, H., Blanco‐Luquin, I., Glaría, E., Arteta-Sanchez, V., Kochan, G. T., & Escors, D. (2016) · Immunotherapy · doi:10.2217/imt-2015-0024 · Cited by 10
Eskander, R. N., & Powell, M. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211001199 · Cited by 10
Analysis of the PD-1 Ligands Among Gastrointestinal Cancer Patients: Focus on Cancer Immunity
Dai, L., Huang, Z., & Li, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637015 · Cited by 10
Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
Su, R., Jin, C., Bu, H., Xiang, J., Zhou, L., & Jin, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861392 · Cited by 11
New Opportunities for Minimizing Toxicity in Rectal Cancer Management
Couwenberg, A. M., Varvoglis, D. N., Grieb, B. C., Marijnen, C. A. M., Ciombor, K. K., & Guillem, J. G. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389558 · Cited by 10
Zeng, Y., Li, N., Zheng, Z., Chen, R., Liu, W., Zhu, J., Zeng, M., Cheng, J., Peng, M., & Hong, C. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s330680 · Cited by 10
Willis, J. E., Temple‐Smolkin, R., Sargent, D. J., Colasacco, C., Minsky, B. D., Sepulveda, A. R., Hamilton, S. R., Singh, V., Monzon, F. A., Grody, W. W., et al. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vf3q-g225 · Cited by 10
Huang, Q., Wang, F., Zhang, X., Liu, J., Dou, X., Feng, R., Zhu, K., Jiang, S., Zhang, Y., & Yue, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11128-2 · Cited by 9
Melanoma Antigen Gene Family in the Cancer Immunotherapy
Yang, L., Zhu, F., Liang, Y., & Chen, D. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.184320 · Cited by 9
Li, L., Gao, H., Wang, D., Jiang, H., Wang, H., Yu, J., Jiang, X., & Huang, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.624951 · Cited by 10
Zhang, Y., Zeng, L., Lin, D., Chang, G., Zeng, Y., & Xia, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1076521 · Cited by 9
“It is reported that TMB can be used as an index to predict ICI efficacy and has become a biomarker in certain cancer types to identify patients who will benefit from immunotherapy (38, 39), which may be related to the fact that high TMBmay produce more neoantigens recognized by the immune system and trigger a broader…”
Lauriola, A., Davalli, P., Marverti, G., Santi, S., Caporali, A., & D’Arca, D. (2023) · Cancers · doi:10.3390/cancers15113009 · Cited by 9
“(Figure 3) Although several predictive biomarkers have been widely investigated for immunotherapy response [156], currently only a few tumor-agnostic biomarkers are FDA-approved [157,158].”
BackgroundFang, L., Yao, Y., Guan, X., Liao, Y., Wang, B., Cui, L., Han, S., Zou, H., Su, D., Ma, Y., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34539 · Cited by 10
Liao, Y., Yang, R., Wang, B., Ruan, Y., Cui, L., Yang, J., Yu, X., Han, S., Yao, Y., Luan, X., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03255-2 · Cited by 9
Argenziano, M., Monge, C., Scomparin, A., Trotta, F., Boscaro, V., Gigliotti, C. L., Stoppa, I., Dianzani, U., Pizzimenti, S., Cavalli, R., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125869 · Cited by 8
Zhang, X., Ji, H., Huang, Y., Zhu, B., & Xing, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13201 · Cited by 9
Liu, Y., Wang, Z., Hao, H., Wang, Y.-P., & Hua, L. (2023) · Immunology · doi:10.1111/imm.13647 · Cited by 10
Zhang, J., Zhang, X., Wang, Q., Xu, Y., Yao, Q., Huang, D., Sheng, W., Zhu, X., Zhou, X., & Bai, Q. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04261-1 · Cited by 8
Zhang, Z., Lei, Y., Wang, D., Liu, Y., & Lou, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968110 · Cited by 8
“Therefore, despite the low incidence of DA, the blockade against immune checkpoints is likely to be a significant opportunity for (35, 36).”
BackgroundVatrano, S., Pettinato, A., Randazzo, V., Zagami, M., Agueli, C., Cannella, S., Banna, G. L., Fraggetta, F., & Santoro, A. (2020) · Pathologica · doi:10.32074/1591-951x-113 · Cited by 8
Dual immune checkpoint blockade strategies for cancer therapy
Liu, Y., Yadav, U. P., Chen, C., & Wang, P. (2026) · Cell investigation. · doi:10.1016/j.clnves.2026.100064 · Cited by 7
Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
Dong, J., Qian, Y., Zhang, G., Lu, L., Zhang, S., Ji, G., Zhao, A., & Xu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.884423 · Cited by 8
Huo, J.-T., Tuersun, A., Yu, S.-Y., Zhang, Y., Feng, W., Xu, Z., Zhao, J., Zong, Y., & Lu, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-48768-0 · Cited by 7
Abad, C. B., Pons, P. G., Ramírez, S. E. C., Alejandro, M. Á., Ramón, M. I. T., Gallart, M. D. M., Álvarez, S. I., Marqués, E. P., & Pazo-Cid, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020367 · Cited by 8
“Immune Checkpoint Inhibitors In the field of immunotherapy, pembrolizumab has been approved to treat solid tumors with high MSI-H or MMR deficiency [107].”
Liu, C., Wang, W., Yang, J., Song, P., Li, F., Liu, B., Li, J., Xu, H., Mi, Y., Tang, Y., et al. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-19-670 · Cited by 7
Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review
Xue, R., Li, R., Wang, J., Tong, W., & Hao, J. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00007 · Cited by 11
ZHAN, J., WANG, W., TANG, Y., Zhou, N., & JIANG, D. (2022) · Biocell · doi:10.32604/biocell.2022.021300 · Cited by 7
Liu, J., Zhang, B., Zhang, Y., Zhao, H., Chen, X., Zhong, L., & Shang, D. (2023) · Aging · doi:10.18632/aging.205194 · Cited by 7
Liang, L., Yang, Y., Deng, K., Wu, Y., Li, Y., Bai, L., Wang, Y., & Lu, C. (2024) · Cells · doi:10.3390/cells13131163 · Cited by 9
Zhu, J., Kong, W., Huang, L., Bi, S., Jiao, X., & Zhu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1142609 · Cited by 8
Zhang, C., Sui, C., Ma, X., Ma, C., Sun, X., Zhai, C., Cao, P., Zhang, Y., Cheng, J., Li, T., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1402448 · Cited by 6
Igase, M., Hagimori, K., Inanaga, S., Mizoguchi, H., ITAMOTO, K., Sakurai, M., Motegi, T., Yamamoto, H., Kato, M., Shiga, T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013623 · Cited by 7
Advances in the therapeutic study of oncolytic virus in colorectal cancer
Chen, J., Chen, K., & Yuan, X. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000051 · Cited by 6
Single-cell genomic profile-based analysis of tissue differentiation in colorectal cancer
Jiang, H., Zhang, H., & Zhang, X. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1811-5 · Cited by 6
Clinical implications of WNT/β-catenin signaling for hepatocellular carcinoma
Asaoka, Y., & Tanaka, A. (2020) · Global Health & Medicine · doi:10.35772/ghm.2020.01099 · Cited by 6
Self-citationZang, L., Zhang, B., Zhou, Y., Zhang, F., Tian, X., Tian, Z., Chen, D., & Miao, Q. (2023) · Aging · doi:10.18632/aging.205293 · Cited by 6
Jeon, H. M., Lee, J. S., Kim, S. H., Yun, K., Park, K.-H., Jeon, M. K., Lee, Y. H., Yoon, H. I., Suh, J., Hur, H., et al. (2020) · Oncology · doi:10.1159/000509004 · Cited by 6
Huo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., & Liang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643133 · Cited by 5
Yu, C., Zhang, D., Chen, C., Xing, S., Li, P., Zhang, Y., Shang, L., Ma, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105191 · Cited by 8
Metadata
- Authors
- Asaoka, Y., Ijichi, H., & Koike, K.
- ORCID
- Hideaki Ijichi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1979-1979
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2597802455
- Cited by
- 426
- References
- 3
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 31 · 2023: 52 · 2022: 46 · 2021: 52 · 2020: 60 · 2019: 45 · 2018: 24 · 2017: 30 · 2016: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-PD-1 therapy, mismatch repair deficiency, cancer immunotherapy, immune checkpoint inhibitors, microsatellite instability, Lynch syndrome, tumor immunology
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasm Metastasis, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.